S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Actinogen Medical Limited (ACW.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.02
52-Week Range N/A
Volume275,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.


Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 8964 7401



Sales & Book Value

Annual Sales$3.52 million
Book ValueA$0.01 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive ACW News and Ratings via Email

Sign-up to receive the latest news and ratings for ACW and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Actinogen Medical Limited (ACW.AX) (ASX:ACW) Frequently Asked Questions

What stocks does MarketBeat like better than Actinogen Medical Limited (ACW.AX)?

Wall Street analysts have given Actinogen Medical Limited (ACW.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Actinogen Medical Limited (ACW.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Actinogen Medical Limited (ACW.AX)'s key competitors?

What other stocks do shareholders of Actinogen Medical Limited (ACW.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinogen Medical Limited (ACW.AX) investors own include Dynavax Technologies (DVAX), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin plc (CEY.L) (CEY), Countryside Properties PLC (CSP.L) (CSP), Enbridge (ENB), EQTEC plc (EQT.L) (EQT) and Exact Sciences (EXAS).

Who are Actinogen Medical Limited (ACW.AX)'s key executives?

Actinogen Medical Limited (ACW.AX)'s management team includes the following people:
  • Dr. John William Ketelbey MBBCH, FFPM, MBA, GAICD, MD, CEO & Director
  • Mr. Jeff Carter, Chief Financial Officer (Age 62)
  • Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 57)

What is Actinogen Medical Limited (ACW.AX)'s stock symbol?

Actinogen Medical Limited (ACW.AX) trades on the ASX under the ticker symbol "ACW."

How big of a company is Actinogen Medical Limited (ACW.AX)?

Actinogen Medical Limited (ACW.AX) has a market capitalization of $0.00 and generates $3.52 million in revenue each year.

What is Actinogen Medical Limited (ACW.AX)'s official website?

The official website for Actinogen Medical Limited (ACW.AX) is www.actinogen.com.au.

How can I contact Actinogen Medical Limited (ACW.AX)?

The company can be reached via phone at 61 2 8964 7401.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.